Bristol-Myers Squibb: Key Facts
 
 
 
Key Facts
Chief Executive Officer:
 Lamberto Andreotti
Headquarters:
 New York City
Business:
 Biopharmaceuticals
Web Address:
 www.bms.com
NYSE Listing:
 BMY
Net Sales:
 $17.6 billion in 2012
R&D Investment:
 $3.9 billion in 2012
2012 Largest-Selling Products:
ABILIFY®, $2.8 billion
PLAVIX®, $2.5 billion
SUSTIVA® franchise, $1.5 billion
REYATAZ®, $1.5 billion
BARACLUDE®, $1.4 billion
ORENCIA® $1.2 billion
SPRYCEL® $1.0 billion
Selected Key Products:
 ABILIFY® (aripiprazole)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
BARACLUDE® (entecavir)
ELIQUIS® (apixaban)
ERBITUX® (cetuximab)
IXEMPRA® (ixabepilone)
KOMBIGLYZE™ (saxagliptin and metformin)
NULOJIX® (belatacept)
ORENCIA® (abatacept)
ONGLYZA® (saxagliptin)
PLAVIX® (clopidogrel bisulfate)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
YERVOY® (ipilimumab)
Principal Locations:
 Worldwide Facilities

Please click on the product links to see the Full Prescribing Information for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, ERBITUX®, IXEMPRA®, KOMBIGLYZE™ XR, NULOJIX®, ONGLYZA®, ORENCIA®, PLAVIX®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, IXEMPRA®, KOMBIGLYZE™ XR, NULOJIX®, PLAVIX®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

January, 2013


 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.